Cyclic Amide Pyridyl-Xanthines for Soluble A2B Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing A2B adenosine receptor antagonists, such as xanthine-based CVT-6883, suffer from low solubility and bioavailability, limiting their therapeutic effectiveness in treating conditions like asthma and COPD.
Innovation Solution
Development of novel cyclic amide-containing pyridyl-xanthines and their pharmaceutically acceptable salts, which act as potent A2B antagonists, improving solubility and tissue penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If xanthine-based A2B antagonists (e.g., CVT-6883) are used, then A2B receptor antagonism is achieved, but solubility and bioavailability are reduced
Solution Approach 1:
The patent modifies the chemical structure of xanthine-based compounds by introducing cyclic amide groups at specific positions (R1, R2, or R3) and incorporating pyridyl moieties, which changes the physical and chemical parameters of the molecule to improve aqueous solubility while preserving A2B receptor binding affinity
Solution Approach 2:
The invention creates composite molecular structures combining xanthine core, cyclic amide groups, and pyridyl rings to form new hybrid compounds that exhibit both improved solubility characteristics and maintained pharmacological activity as A2B antagonists
2Reliability
If xanthine-based A2B antagonists (e.g., CVT-6883) are used, then A2B receptor antagonism is achieved, but tissue penetration is poor
Solution Approach 1:
The patent optimizes molecular parameters including size, polarity, and hydrophobicity through strategic placement of cyclic amide and pyridyl groups, enabling the compounds to achieve adequate tissue penetration while maintaining their antagonistic activity at A2B receptors
3Reliability
If conventional A2B antagonists are used, then receptor binding is achieved, but bioavailability is low
Solution Approach 1:
The invention modifies key physicochemical parameters of the xanthine scaffold including molecular weight, logP, and hydrogen bonding capacity through incorporation of cyclic amide and pyridyl groups, thereby improving oral bioavailability while preserving receptor binding affinity
Data Source
AI summary
Described herein are cyclic amide-containing pyridyl-xanthines of formula I and pharmaceutical compositions thereof that are useful as antagonists of A2B adenosine receptors.